TICKERNERD
Menu
VNRXVNRXHealthcare · Medical Devices

VNRX Stock Forecast: VolitionRX Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.42
−5.25% on the day

The 5 Wall Street analysts covering VolitionRX Ltd. hold a median 12-month price target of $20 — +4697.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.7M
Ticker Nerd rank
35 / 100
Median analyst target
$20
Analysts covering
5
Total return, dividends reinvested
1W
−22.8%
1M
−62.4%
YTD
−92.0%
1Y
−96.9%
From 52W high
−97.0%
From 52W low
0.0%
$0
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VNRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VolitionRX Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Accruals
77
Growth
76
Revisions
61
Volatility
35
Quality
19
Value
14
Momentum
12
Issuance
9

Size (96): Smaller than most of the companies we track.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VNRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VNRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26VNRXHigh $24Median $20Low $2

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $2Median $20High $24

The green dot is the last close — the median target sits +4697.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Apr 2026D. Boral CapitalDowngradeHold—
2 Apr 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026D. Boral CapitalMaintainsBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
9 Jan 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
4 Dec 2025D. Boral CapitalMaintainsBuy—
3 Dec 2025Maxim GroupDowngradeHold—
26 Nov 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025Freedom BrokerMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
17 Nov 2025HC Wainwright & Co.MaintainsBuy—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
29 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
17 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VNRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VNRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

VolitionRX Ltd. (VNRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
−0.1×

Cheaper than 93% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
−2.0%

Higher than 24% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1042.5%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
65.6%

Higher than 94% of US stocks

Return on assets
−142.9%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VNRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VNRXVolitionRX Ltd.$5.7M
35
WOKWORK Medical Technology Group Ltd.$5.7M
16
VVOSVivos Therapeutics, Inc.$6.0M
25
AMIXAutonomix Medical, Inc.$5.1M
12
ITOCiTonic Holdings Ltd.$5.0M
23
BMRABiomerica, Inc.$4.9M
35
XAIRBeyond Air, Inc.$4.8M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own VolitionRX Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VNRX news & analysis

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

VolitionRx Limited held its Q2 2026 earnings call, during which management discussed the company's quarterly financial results and operational highlights. A transcript of the call has been published on Seeking Alpha.

Why it matters — VNRX watchers can review management's commentary and forward-looking statements from the earnings call for insights into the company's financial position and strategic progress.

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

PRNewsWire · 13 Aug 2026neutral

VolitionRx Limited announced its second quarter 2026 financial results and business update, with a conference call to discuss the operational and financial results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time.

Why it matters — VolitionRx watchers would care because the announcement provides the company's latest quarterly financial position and operational update, along with a scheduled call to detail these results.

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

PRNewsWire · 12 Aug 2026positive

VolitionRx announced that results from its lateral flow prototype point-of-care finger-prick test are highly correlated with results from its established automated Nu.Q® NETs test in critically ill sepsis patients. The finding demonstrates the test's utility beyond centralized laboratory testing.

Why it matters — The announcement indicates validation for a rapid, point-of-care version of Volition's NETosis testing, which could broaden its potential application beyond centralized laboratory settings.

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

PRNewsWire · 11 Aug 2026neutral

VolitionRx Limited announced it will host its second quarter 2026 earnings conference call and business update on Friday, August 14 at 8:30 a.m. U.S. Eastern Time. The company, based in Henderson, Nevada, published the schedule via press release.

Why it matters — A VolitionRx watcher would care because the upcoming call provides the scheduled opportunity to hear the company's Q2 2026 financial results and latest business developments.

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

PRNewsWire · 5 Aug 2026positive

VolitionRX announced the publication of the first peer-reviewed paper on its new Capture-Seq™ liquid biopsy technology, which targets a $36 billion total addressable market in early cancer detection and minimal residual disease (MRD) testing.

Why it matters — The publication provides external validation of Volition's new platform, and the company's active discussions with global diagnostic leaders suggest potential commercialization pathways are being explored.

FAQ

Frequently asked questions about VNRX stock

What is the VNRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering VolitionRX Ltd. have a median 12-month price target of $20, with estimates ranging from $2 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VNRX stock a buy right now?

Of the 5 analysts covering VolitionRX Ltd., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks VolitionRX Ltd. 35 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VNRX?

As at 22 Aug 2026, VolitionRX Ltd. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will VNRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +4697.3% from the last close, and Ticker Nerd's factor model ranks VolitionRX Ltd. 35 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VNRX stock forecast for 2030?

No analyst covering VolitionRX Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $24 over the next 12 months.

How has VNRX stock performed over the past year?

VolitionRX Ltd. returned -96.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VolitionRX Ltd. do?

VolitionRx Limited is a multinational epigenetics company specializing in the development and commercialization of blood-based diagnostic tests. Its primary focus is on applying its proprietary Nucleosomics platform to detect and measure nucleosomes and related biomarkers in blood and other bodily fluids, supporting the diagnosis and monitoring of life-altering diseases, including certain cancers and conditions associated with NETosis such as sepsis.

What is the latest news on VNRX?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript". VolitionRx Limited held its Q2 2026 earnings call, during which management discussed the company's quarterly financial results and operational highlights. A transcript of the call has been published on Seeking Alpha.

Company

About VolitionRX Ltd.

VolitionRx Limited is a multinational epigenetics company specializing in the development and commercialization of blood-based diagnostic tests. Its primary focus is on applying its proprietary Nucleosomics platform to detect and measure nucleosomes and related biomarkers in blood and other bodily fluids, supporting the diagnosis and monitoring of life-altering diseases, including certain cancers and conditions associated with NETosis such as sepsis. The company aims to provide simple, easy-to-use, and cost-effective assays that can be integrated into routine clinical workflows, helping healthcare providers obtain actionable information on disease presence and progression. VolitionRx today operates through a network of subsidiaries, with research and development centered in Belgium and additional operations in the United States, United Kingdom, and Singapore. Headquartered in Henderson, Nevada, and founded in 2010, VolitionRx Limited serves the global human and veterinary diagnostics markets, offering tools that support earlier detection and ongoing treatment monitoring across multiple therapeutic areas.

CEO Mr. Cameron Reynolds MBA · 57 employees · United States · https://volition.com